Fig. 1

IL-20RA and RANKL in FLS from RA patients. a RA- and OA-FLSs were simultaneously labeled with anti-IL-20RA (green) and anti-RANKL (red) antibodies and then photographed under appropriate filters (n = 3). b RA and OA-FLSs were simultaneously labeled with anti-CD55 (green) and anti-RANKL (red) antibodies and then photographed under appropriate filters (n = 3). c RA and OA-FLSs were simultaneously labeled with anti-CD55 (green) and anti-IL-20RA (red) antibodies and then photographed under appropriate filters (n = 3). The merged image shows co-localization of the two markers (yellow). Sections were counterstained with 4′,6-diamidino-2-phenylindole. Images are representative of three independent experiments (original magnification × 200). d RA-FLSs were cultured with IL-26 at various concentrations, and IL-20RA and IL-10 receptor subunit B mRNA levels were determined by real-time polymerase chain reaction (n = 3). Results are expressed as the SEM of three independent experiments. ***P < 0.005. IL-20RA interleukin (IL)-20 receptor subunit A, RANKL receptor activator of nuclear factor-kappaB ligand, FLSs fibroblast-like synoviocytes, RA rheumatoid arthritis, OA osteoarthritis